News
Cyclomics: Winner of the Venture Challenge Fall 2017
Today at the Dutch Life Sciences Conference 2017, Chrétien Herben, director of the LifeSciences@Work Accelerator, announced Cyclomics as winning team of the 18th edition of the Venture Challenge. The start-up Cyclomics has developed a technology to measure cancer recurrence in liquid biopsies, by detection of cancer mutations in blood at single-molecule sensitivity. This way the start-up aims to improve survival for many different types of cancer.
EMA to relocate to Amsterdam, the Netherlands
The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. The agency is responsible for the approval of medicines on the European market. EMA has to relocate due to the United Kingdom’s decision to withdraw from the EU. The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.
AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Joint Committee on Cancer (AJCC) has recently issued a Breast Cancer Update and Correction which revised and clarified the Cancer Staging Manual, 8th Edition regarding the use of multigene genomic profiles for Pathological Prognostic Staging.
Animal-friendly and effective medicine test Mimetas receives second innovation credit
Het Leidse bedrijf Mimetas ontvangt tijdens het bezoek van staatssecretaris Keijzer van Economische Zaken en Klimaat (EZK) een tweede Innovatiekrediet ter waarde van € 2 miljoen. Mimetas benut deze steun voor de doorontwikkeling van personalized medicine: bijvoorbeeld een tool om de oncoloog te helpen bij de behandelkeuze van verschillende kankers.
Building on Cures Act, FDA lays out cell therapy fast track in regenerative medicine framework
The FDA has created a policy framework for cellular therapies and other regenerative medicines by releasing two draft and two final guidance documents. Publication of the texts builds on the 21st Century Cures Act by setting criteria for the new Regenerative Medicine Advanced Therapy (RMAT) designation and outlining the benefits of the regulatory status.
hDMT seeks collaborators for €4M NWO-TTW Perspectief Program proposal
hDMT is the Dutch Organ-on-Chip consortium, with currently near 100 affiliated research leaders. hDMT’s researchers work in fourteen academic research institutions, university medical centers and biotechnology companies. They share their knowledge and expertise to develop Organ-on-Chip models, by integrating state-of-the-art human stem cell technologies and top level engineering with a wide variety of other disciplines.
Xeltis Closes €45 Million Series C Financing
Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C financing.
Unique collaboration IPH with the four big healthcare insurers
Het Institute for Positive Health (iPH), VGZ, Menzis, CZ en Zilveren Kruis tekenden vandaag een overeenkomst waarmee zij gezamenlijk hun maatschappelijke taak en verantwoordelijkheid laten zien om de patiëntgerichte zorg te bevorderen.
Your chance to determine which countries & regions get priority!
In welke landen ziet u kansen? Welke belemmeringen verdienen aandacht? Welke ondersteuning vindt u belangrijk? Laat het ons weten in het onderzoek Internationale Kansen & Knelpunten 2018!
Starting capital for Amylon Therapeutics
Op 7 november 2017 ontving Amylon Therapeutics, een spin-off van het Leidse, NASDAQ-genoteerde ProQR Therapeutics, een investering van € 300.000 van investeringsfonds UNIIQ voor de ontwikkeling van een kandidaatmedicijn tegen de Katwijkse Ziekte, een ongeneeslijke, erfelijke aandoening die gekenmerkt wordt door hersenbloedingen.